Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. Ng TI, et al. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01620-17. doi: 10.1128/AAC.01620-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29084747 Free PMC article.
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A. Mo H, et al. Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14. doi: 10.1128/AAC.49.10.4305-4314.2005. Antimicrob Agents Chemother. 2005. PMID: 16189112 Free PMC article.
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.
Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. Pilot-Matias T, et al. Antimicrob Agents Chemother. 2015 Feb;59(2):988-97. doi: 10.1128/AAC.04227-14. Epub 2014 Dec 1. Antimicrob Agents Chemother. 2015. PMID: 25451053 Free PMC article. Clinical Trial.
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Krishnan P, et al. Antimicrob Agents Chemother. 2015 Sep;59(9):5445-54. doi: 10.1128/AAC.00998-15. Epub 2015 Jun 22. Antimicrob Agents Chemother. 2015. PMID: 26100711 Free PMC article.
Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Schnell G, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15. doi: 10.1128/AAC.01229-15. Epub 2015 Aug 17. Antimicrob Agents Chemother. 2015. PMID: 26282418 Free PMC article. Clinical Trial.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Krishnan P, et al. Antimicrob Agents Chemother. 2015 Dec 7;60(2):1106-13. doi: 10.1128/AAC.02606-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26643326 Free PMC article. Clinical Trial.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.
Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. Ng TI, et al. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28193664 Free PMC article.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L Jr, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Schnell G, et al. J Med Virol. 2018 Jan;90(1):109-119. doi: 10.1002/jmv.24923. Epub 2017 Sep 22. J Med Virol. 2018. PMID: 28842997 Free PMC article. Clinical Trial.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T. Krishnan P, et al. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29180522 Free PMC article. Clinical Trial.
87 results